Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 2,762

Document Document Title
WO/2008/157635A2
Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.  
WO/2008/149563A1
It is intended to provide a VDR ligand which does not induce hypercalcemia that is the side effect of a vitamin D3 preparation. A composition which contains lithocholic acid propionate, its salt or a solvate or prodrug of the same.  
WO/2008/136199A1
A process for producing a compound represented by the following formula (2): (2) (wherein R1 means hydrogen, methyl, or CH2OH; R2 means hydrogen or methyl; R3 means hydrogen or hydroxy; R4 means hydrogen or hydroxy; and R5 means hydroxy,...  
WO/2008/128783A2
The invention is directed to a photochemical process for the preparation of a previtamin D or a derivative thereof from a 7-dehydrosterol or a corresponding derivative thereof which process comprises irradiating the 7-dehydrosterol or th...  
WO/2008/110941A2
The invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor like 24-substituted oxy-7-substitutedoxycholestan-3- one, preferably of 24β-benzoyloxy-7α-hydroxycholestan-3-one.  
WO/2008/091540A2
The invention relates to compounds of Formula A: (A) or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including obes...  
WO/2008/084561A1
It is intended to provide a Helicobacter pylori growth inhibitor which can be produced very simply in a large amount, contains a compound specifically inhibiting Helicobacter pylori growth, is safe and does not cause a resistant bacteriu...  
WO/2008/074216A1
The invention provides sterols modified by polyethylene glycol represented by the following formula, the preparation and the use thereof, wherein each symbol is defined as in the description.  
WO/2008/071009A1
This application relates to micelle-forming poly(ethylene oxide)-block-poly(ester) block copolymers having reactive groups on both the poly(ethylene oxide) block and the poly(ester) block therein. The biodegradability of these copolymers...  
WO/2008/071960A2
This invention relates to the promotion of neurogenesis in progenitor or precursor cells by modulation of the amount of liver X receptor (LXR) signalling in said cells. Increased LXR signalling is shown herein to promote neurogenesis and...  
WO/2008/041003A2
The present invention provides the use of an LXR antagonist, or a physiologically- acceptable pro-drug therefor, in the manufacture of a medicament for combating insulin resistance or a disorder associated therewith. Further provided is ...  
WO/2008/038965A1
Disclosed are 7α-aminosteroid derivatives or pharmaceutically acceptable salts thereof, preparation methods thereof, and anticancer or antibiotic compositions comprising the same as an active ingredient. Reductive amination with amine i...  
WO/2008/032980A1
The present invention relates to a novel stigmasterol derivative or a pharmaceutically acceptable salt thereof, a method of producing the same, and a composition comprising the same for inhibiting obesity or for preventing and treating h...  
WO/2008/008810A2
A process is described for efficiently recovering at least one of phytosterols and tocopherols in substantially pure form from the deodorizer distillates that may be obtained as by-products of the refining of edible oils. The phytosterol...  
WO/2008/000068A1
The present invention relates to a new method of preparing 2-iodo triterpenoid and related compounds via the reaction of the corresponding 1 ene-3-ones in the presence of iodine and pyridine in an ether solvent. The method is particularl...  
WO/2007/145253A1
The object is to provide a highly safe NF-κB activation inhibitor at a low cost which can be used for the prevention or treatment of a disease associated with the activation of NF-κB such as an inflammation or type-2 diabetes. Specific...  
WO/2007/112573A1
The present invention describes nitrate esters of sterols and stanols that bear an ascrobic acid moiety and a phosphate linking group, as well as pharmaceutically acceptable salts and stereoisomers thereof The invention also provides nov...  
WO/2007/112572A1
The present invention describes nitrate esters of sterols and stanols that bear a benzoic acid moiety as a linking group, as well as pharmaceutically acceptable salts and stereoisomers thereof The invention also provides novel compositio...  
WO/2007/101581A2
The invention relates to a powder formulation containing sterol in the form of a super-cooled melt from sterols and sterol esters, under the proviso that the sterol ester content is at least 30 wt % in relation to the content of the powd...  
WO/2007/101580A2
The invention relates to sterol fatty acid esters of average chained fatty acids, having a chain length of 8 and 10 carbon atoms in a fatty acid distribution C8 to C10 (weight ratio) from 95:5 to 5:95, preferably, fatty acid distribution...  
WO/2007/100080A1
[PROBLEMS] To provide a method by which the benzyl position in an -O-benzyl group formed by introducing benzyl, benzyloxymethyl, or the like as a hydroxy-protecting group is efficiently and industrially deuterized. [MEANS FOR SOLVING PRO...  
WO/2007/094218A1
A modified oligonucleotide comprising an oligonucleotide containing at its 3’end a modified nucleoside as a structural component, wherein the modified nucleoside is one having a carboxylic acid or steroid skeleton containing compound l...  
WO/2007/095174A2
The present invention relates to compounds of formula (I) wherein: Ri is hydrogen or an alkyl group; R2 is hydrogen or a halogen, nitro, alkyloxy, amino or carboxy group; Y is CH2, oxygen or sulfur; n is an integer from 1 to 4, and pharm...  
WO2006044575A9
A method for preparing an aliphatic chloroformate comprising, introducing a mixture of at least one aliphatic hydroxyl compound, phosgene, at least one solvent, and optionally at least one organic base into a flow reactor to obtain a uni...  
WO/2007/080951A1
The invention provides a novel process for the production of steroids, namely, a process for the production of 5β-3,7 -dioxocholanoic acid or ester derivatives thereof which comprises using as the raw material a sterol having double bon...  
WO/2007/076656A1
A synthesis process of cholest-5-en-3β,19-dihydroxy-24-one and its derivatives includes the steps of: synthesis of 3β-acetoxy-cholest-5-en-24-acid with hyodesoxycholic acid as the starting material; synthesis of 3β-acetoxy-cholest-5-e...  
WO/2007/076655A1
A synthesis process of cholest-3β,5α,6β,19-tetrahydroxy-24-one and its derivatives includes the steps of: synthesis of 3β-acetoxy-cholest-5-en-24-acid with hyodesoxycholic acid as the starting material; synthesis of cholenic acid chl...  
WO/2007/069814A1
The present invention relates to a process for purifying chenodeoxycholic acid (3α,7α-dihydroxy-5β-cholic acid). In particular, the present invention relates to a process for purifying chenodeoxycholic acid from low grade of chenodeox...  
WO2007043294A9
Disclosed is a pharmaceutical or beverage/food which can reduce the fat accumulated in the abdominal cavity and can prevent or ameliorate visceral obesity which is believed to be the primary cause of metabolic syndrome. The pharmaceutica...  
WO/2007/060911A1
Disclosed is an aloe vera extract which is safe to ingest, can be used as a food material for use in the prevention of a life-style related disease, has extremely less contamination of an anthraquinone (an anthraquinone compound) and can...  
WO/2007/054759A1
The present invention provides an isolation process of the pure sterols from the SODD by simple acid catalyzed esterification and the separation of the reagents by distillation and water washing followed by the crystallization of phytost...  
WO/2007/043302A1
Disclosed is a pharmaceutical or beverage/food which can inhibit the production of an adipocytokine, particularly an adipocytokine that can induce the resistance to insulin, to thereby prevent or ameliorate the occurrence of a morbid con...  
WO/2007/043306A1
Disclosed is a pharmaceutical or beverage/food which can inhibit the production of an adipocytokine, particularly an adipocytokine that can induce the resistance to insulin, to thereby prevent or ameliorate the occurrence of a morbid con...  
WO/2007/039346A2
A photoresist composition including a polymer, a photoacid generator and a dissolution modification agent, a method of forming an image using the photoresist composition and the dissolution modification agent composition. The dissolution...  
WO/2007/026869A1
A sugar-cholestanol compound having a sufficient antitumor activity is provided by a simple synthesis. Disclosed is an antitumor agent containing a cholestanol compound represented by the formula (1) below or a cyclodextrin clathrate the...  
WO/2007/022089A2
As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cholesterol oxidation or ozonation products that can act as chemotactic attractants of macrophages, can promote differe...  
WO/2007/016630A1
A fortified beverage is provided that comprises a sterol ester, stanol ester, or combinations thereof; and an aqueous medium. Methods of making such beverage are also provided.  
WO/2007/006549A2
The invention relates to novel substances derived from cholesterol, cholesterol sulfate and cholesterol esters of natural, semi-synthetic or synthetic origin, such that they represent oligomers with a specific type of link to starting su...  
WO/2006/122977A2
Process for preparing 3α-7α(β)-dihydroxy-6α(β)-alkyl-5β-cholanic acid (I) in which R is a linear or branched C1-C5 alkyl and the relative intermediates 3α-hydroxy-6β-alkyl-7-keto-5β-cholanic (VIII) and 3α-hydroxy-6α-alkyl-7-ke...  
WO/2006/123465A1
Use of compounds having pancreatic function improving activities, for example, 4-methylcholest-7-en-3-ol, 4-methylergost-7-en -3-ol, and 4-methylstigmast-7-en-3-ol in drugs, food or drink for improving pancreatic functions as the active ...  
WO/2006/112446A1
This invention provides a positive-working resist composition, which uses a low-molecular material as a base component and can form a high-resolution resist pattern, and a method for resist pattern formation, a compound suitable for the ...  
WO/2006/090910A1
A novel steroid glycoside having an NGF-associated activity, represented by the general formula: (1) This steroid glycoside has an NGF-associated activity.  
WO/2006/079731A2
The invention relates to the use of cacao polyphenols for preventing or curing a prostate hyperplasia, to a cacao polyphenol extract which also comprises, in particular lipids and/or xanthines, and to the applications of said extract in ...  
WO2004085458A9
A steroid comprising a 17-spirolactone or corresponding open lactone structure is obtained by carbonylation of a 17-alkenyl or 17-alkynyl substrate. A 17-alkenyl intermediate may be prepared by semi-hydrogenation of a 17-alkynyl group. M...  
WO/2006/052263A1
Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropy...  
WO/2006/047022A1
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear steroid metabolite that increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol. Methods which involve th...  
WO/2006/045745A1
A process is described for preparing, exclusively by chemical way, 21-hydroxy steroids having progestinic activity, said process having a high stereochemical control at C-21 position.  
WO/2006/024296A1
The present invention relates to processes for epimerising alcohols of compounds having a hydroxyl substituent on an asymmetric allylic carbon, such as compounds useful for the synthesis of vitamin D analogues where the epimeric hydroxyl...  
WO/2006/018019A2
The invention relates to an inhibitor of 11ß hydroxysteroid dehydrogenase (11ß-HSD), which exclusively inhibits 11ß hydroxysteroid dehydrogenase type 1, but not 11ß hydroxysteroid dehydrogenase type 2.  
WO/2006/010307A1
A synthetic method of 20 (s)-ginsenoside Rh2, i. e. 20(S)-protopanaxdiol - 3 - 0 - β - D - glucopyranoside, comprising: selectively protecting protopanaxadiol first to afford monosubstituted protopanaxadiol, and Glycosidating the monosu...  

Matches 401 - 450 out of 2,762